

同意書 編號 AS-IRB02-106214 NUM : 日期 2017/08/23 Date :	<b>中央研究院醫學研究倫理委員會</b> <b>研究計畫審查通過證明</b> <i>Certificate of Approval</i>	IRB02 修訂日期 Revised Date : 1217' 2015
---	--	---

申請案編號 Application No : AS-IRB01-16026(R2)

計畫名稱 Project title : 開發台灣重大癌症異常蛋白質體網絡之蛋白質標記及藥物標靶(旗艦型計畫1)  
Deep Genome, Proteome, and PTMome analysis for discovering biomarker and drug targets in Taiwan Cancers (Flagship 1)

申請人 Project Investigator : 陳玉如 Yu-Ju Chen

合作機構 Collaborating Institute(s) :  
沈志陽 / 生物醫學科學研究所  
俞志誠 Jyh-Cherng Yu / 三軍總醫院一般外科Department of Surgery, Division of General Surgery  
陳晉興 Jin-Sing Chen / 台大醫學院醫學系外科部Department of Surgery, College of Medicine, National Taiwan University  
楊泮池 Pan-Chyr Yang / 台大醫院內科部Department of Internal Medicine, College of Medicine, National Taiwan University  
俞松良 Sung-Liang Yu / 台大醫學院醫學檢驗暨生物技術學系Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University  
潘思樺 Szu-Hua Pan / 國立臺灣大學醫學院基因體暨蛋白質體醫學研究所Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University  
韓嘉莉 Chia-Li Han / 台北醫學大學臨床藥物基因體學暨蛋白質體學碩士學位學程Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University  
徐紹勛 Hsao-Hsun Hsu / 台大醫院一般外科Department of Surgery, National Taiwan University Hospital  
郭順文 Shuenn-Wen Kuo / 台大醫院一般外科Department of Surgery, National Taiwan University Hospital  
林孟暉 Meng-Wei Lin / 台大醫院一般外科Department of Surgery, National Taiwan University Hospital

執行期間 Project Duration: Recruitment from 2016/07/04 to 2019/12/31

核准日期 Approval Date : 2017/08/23

有效期限 Due Date : From 2017/08/23 to 2019/12/31

進度或成果報告 Progress Report :

- 請於 2018/07/03 前繳交進度或成果報告至本委員會追蹤審查。  
The progress report should be submitted to the IRB at Academia Sinica before 2018/07/03 for continuing review.
- 如向衛生福利部定期提出進度或成果報告，需將完整報告內容副知本委員會。  
If Progress reports are submitted to the Department of Health, a copy should be submitted to the IRB at Academia Sinica.
- 如研究對象有不良反應，應即時向主管機關報告並副知本委員會。  
All the adverse events are required to be reported to the official institute and IRB of Academia Sinica promptly.

附註意見 Additional Opinion :

欲檢閱者，請向本委員會依程序申請。

提醒事項 Reminder :

- 1.若需與研究對象溝通（如與研究對象通信、致贈禮物等），與研究對象溝通之文件、信件或禮物，須經本委員會審核通過後方可進行。Any materials (correspondence, brochure, compensation, etc.) provided to subjects, must be approved by the IRB of Academia Sinica.
- 2.未經本委員會審核通過即實施研究或變更研究計畫內容者，不得使用或保存於審查通過或同意變更前收集之檢體或資料。計畫主持人或其他成員仍予使用或保存者，主管機關得依人體研究法第22條處計畫主持人之研究機構新臺幣10萬元以上、100萬元以下之罰鍰、命令終止研究及公布研究機構名稱。

Amendments of an approved research protocol shall be submitted for IRB approval prior to its implementation. Where any research entity affiliated principal investigator or research personnel are subject to violate of that, the responsible ministry of central government may fine the research entity a penalty in the amount of no less than NT\$100,000 nor more than NT\$1,000,000, may terminate the research, and may publish the name of the research entity so penalized.

---

茲 證明上項醫學研究計畫(AS-IRB-BM-16026 v.3)，包括計畫書、研究對象說明同意書、問卷，已經本委員會之審核，並同意此計畫之內容符合本委員會所訂定之醫學研究倫理標準。

The above named study proposal(AS-IRB-BM-16026 v.3) has been reviewed, along with the informed consent form, and questionnaire, and found to conform with the guidelines set forth by IRB on Biomedical Science Research / IRB-BM Academia Sinica.

